Intermittent 'as needed' ICS showed no clear difference in overall withdrawals (duration 12 to 52 weeks) compared with daily ICS (low certainty).
It is very uncertain whether intermittent oral levetiracetam changes recurrent seizures at 12 months compared with placebo (any antipyretics) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Continuous showed no clear difference in all‐cause mortality compared with intermittent Antibiotic Infusions (moderate certainty).
Continuous showed no clear difference in infection recurrence compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in clinical cure compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in super‐infection compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in serious adverse events compared with intermittent Antibiotic Infusions (low certainty).
Continuous showed no clear difference in withdrawal due to adverse events compared with intermittent Antibiotic Infusions (low certainty).
It is very uncertain whether continuous changes adverse events compared with intermittent Antibiotic Infusions (very low certainty).
14 days on/off antibiotic regimen probably leads to lower exacerbation frequency compared with 14 days on/off placebo regimen (moderate certainty).
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
28 days on/off antibiotic regimen leads to higher antibiotic resistance compared with 28 days on/off placebo regimen (high certainty).
28 days on/off antibiotic regimen showed no clear difference in hospitalisation for pulmonary exacerbations compared with 28 days on/off placebo regimen (high certainty).